Treatment of Rapidly Progressive Glomerulonephritis in Anti-GBM Antibody-Positive Disease
Anti-glomerular basement membrane (anti-GBM) antibody glomerulonephritis is a distinct and serious cause of rapidly progressive glomerulonephritis (RPGN). The presence of circulating anti-GBM antibodies drives aggressive glomerular injury, and outcomes for both patient and kidney survival are poor without prompt, targeted intervention.
Clinical Scenario
This protocol applies to patients with confirmed anti-GBM antibody positivity presenting with the clinical picture of RPGN. Recognition of this specific antibody-mediated mechanism is essential, as it defines both the urgency of treatment and the therapeutic strategy.
Treatment Approach
The first-line approach involves combined immunosuppressive therapy together with plasmapheresis; when pulmonary hemorrhage is also present, the regimen incorporates additional measures.
Full regimen — specific agents, sequencing, and dosing — is available in the complete structured protocol below.
References
DOI: 10.1007/s10157-015-1218-8
- In patients with anti-GBM antibody glomerulonephritis presenting with RPGN, the combined use of corticosteroids and immunosuppressive agents, in addition to plasmapheresis, is suggested as the standard treatment.
- Patient survival and kidney survival in anti-GBM antibody-positive RPGN are poor.
- The clinical guideline in Japan recommends immunosuppressive therapy (corticosteroids and cyclophosphamide) plus plasmapheresis. We recommend cyclophosphamide (1–2 mg/kg/day) for patients with refractory GN. However, it is necessary to reduce the dose of cyclophosphamide in patients with advanced renal dysfunction.
- In patients with anti-GBM antibody disease presenting with RPGN, adding intravenous pulse corticosteroid therapy to oral corticosteroids is recommended to improve survival when pulmonary hemorrhage is present (i.e., Goodpasture syndrome).
- Therefore, initial therapy with corticosteroids alone is recommended, usually combined with plasmapheresis, in cases in which the use of immunosuppressive agents is not desirable because of adverse effects.
View source ↗